title: Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
abstract: OBJECTIVE
  Does conditioning with fractionated total body irradiation (fTBI) or busulfan (Bu) causes less salivary dysfunction compared with single dose (sTBI) after hematopoietic stem cell transplantation (HSCT).
  
  
  METHODS
  A total of 74 adolescents below 13 years of age received allogeneic HSCT and conditioning with either: sTBI, fTBI or Bu. The unstimulated (USSR) and stimulated (SSSR) whole salivary secretion rates were measured at 15 years of age.
  
  
  RESULTS
  Irrespective of conditioning type, there were no significant differences in USSR or SSSR between groups. Girls had a significantly lower SSSR, 0.7 ± 0.3 ml per min compared with 1.1 ± 0.4 ml per min in boys (P < 0.001). A significant correlation between age at HSCT and SSSR at 15 years of age (P = 0.02) in children conditioned with sTBI was found as well as an inverse correlation between the plasma area under curve (AUC) of Bu and SSSR. In the multivariate model, only female sex was significantly correlated with low SSSR at 15 years of age (OR 3.93, 95% CI 1.21-12.79; P = 0.021).
  
  
  CONCLUSIONS
  No differences in long-term whole salivary function after HSCT in adolescents receiving conditioning with sTBI, fTBI or Bu were found. Total systemic exposure to Bu was negatively correlated with stimulated salivary secretion.
authors: Division of Oral and Maxillofacial Surgery, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden. karin.garming.legert@ki.se
authors: K
authors: K
authors: Garming-Legert
authors: M
authors: M
authors: Remberger
authors: O
authors: O
authors: Ringdén
authors: M
authors: M
authors: Hassan
authors: G
authors: G
authors: Dahllöf
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000741:Anemia, Aplastic / Q000601:surgery; D019540:Area Under Curve; D002066:Busulfan / Q000097:blood / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006105:Granulomatous Disease, Chronic / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery; D015470:Leukemia, Myeloid, Acute / Q000601:surgery; D008137:Longitudinal Studies; D051359:Lymphohistiocytosis, Hemophagocytic / Q000601:surgery; D016399:Lymphoma, T-Cell / Q000601:surgery; D008297:Male; D009190:Myelodysplastic Syndromes / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D012469:Salivary Glands / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D012636:Secretory Rate / Q000187:drug effects / Q000528:radiation effects; D012737:Sex Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan